Literature DB >> 35478149

ALK Protein Expression Patterns in Squamous Cell Carcinoma of the Oral Cavity.

Aristeidis Chrysovergis1, Vasileios Papanikolaou1, Nicholas Mastronikolis2, Evangelos Tsiambas3,4, Spyros Katsinis5, Arezina Manoli5, Sotirios Papouliakos6, Vasileios Ragos4, Pavlos Pantos1, Dimitrios Peschos7, Stylianos Mastronikolis8, Panagiotis Fotiades9, Panagiotis Mamoulidis1,10, Despoina Spyropoulou11, Efthymios Kyrodimos1.   

Abstract

BACKGROUND: Oral squamous cell carcinoma (OSCC) is characterized by a broad spectrum of genomic imbalances, including gross chromosomal (polysomy/aneuploidy) ones as well as specific gene alterations. Aberrant expression of anaplastic lymphoma kinase (ALK) seems to be a useful molecular marker for discriminating patients based on genetic signatures in a variety of solid malignancies, such as lung carcinoma. Our aim was to analyze ALK protein expression patterns in a series of OSCCs.
MATERIALS AND METHODS: Fifty (n=50) OSCC tissue sections were analyzed by implementing an ALK-based immunohistochemistry protocol. Digital image analysis was performed for measuring the corresponding protein expression levels.
RESULTS: ALK overexpression was observed in 14/50 (28%) OSCC tissue sections, whereas the rest 36/50 (72%) demonstrated low expression levels. ALK expression was negatively associated with grade (p=0.027) and stage (p=0.0028) of the examined cases.
CONCLUSION: Abnormal ALK expression in subsets of patients with OSCC seems to be related to an aggressive phenotype (advanced stage/progressive dedifferentiation). ALK protein overexpression may be used as a significant marker for applying targeted therapeutic regimens.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  ALK; Carcinoma; gene; oral cancer; protein; tyrosine kinase inhibitors

Mesh:

Substances:

Year:  2022        PMID: 35478149      PMCID: PMC9087091          DOI: 10.21873/invivo.12813

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  31 in total

Review 1.  Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.

Authors:  Johan F Vansteenkiste
Journal:  Future Oncol       Date:  2014-05-23       Impact factor: 3.404

2.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-06-26       Impact factor: 91.245

3.  Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor.

Authors:  Ferdinandos Skoulidis; Vassiliki A Papadimitrakopoulou
Journal:  Clin Cancer Res       Date:  2016-09-08       Impact factor: 12.531

Review 4.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

5.  Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.

Authors:  T Iwahara; J Fujimoto; D Wen; R Cupples; N Bucay; T Arakawa; S Mori; B Ratzkin; T Yamamoto
Journal:  Oncogene       Date:  1997-01-30       Impact factor: 9.867

Review 6.  Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.

Authors:  Eric K Singhi; Leora Horn; Lecia V Sequist; John Heymach; Corey J Langer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2019-05-17

Review 7.  Co-evolution of tumor cells and their microenvironment.

Authors:  Kornelia Polyak; Izhak Haviv; Ian G Campbell
Journal:  Trends Genet       Date:  2008-12-04       Impact factor: 11.639

8.  Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas.

Authors:  Tze-Ta Huang; Cara B Gonzales; Fei Gu; Ya-Ting Hsu; Rohit R Jadhav; Chiou-Miin Wang; Spencer W Redding; Chih-En Tseng; Ching-Chih Lee; Ian M Thompson; Hau-Ren Chen; Tim Hui-Ming Huang; Nameer B Kirma
Journal:  Carcinogenesis       Date:  2013-04-08       Impact factor: 4.944

Review 9.  Mutational heterogeneity in human cancers: origin and consequences.

Authors:  Jesse J Salk; Edward J Fox; Lawrence A Loeb
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

10.  Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response.

Authors:  Carolien Boeckx; Christine Weyn; Isabelle Vanden Bempt; Vanessa Deschoolmeester; An Wouters; Pol Specenier; Carl Van Laer; Danielle Van den Weyngaert; Mark Kockx; Jan B Vermorken; Marc Peeters; Patrick Pauwels; Filip Lardon; Marc Baay
Journal:  BMC Res Notes       Date:  2014-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.